Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer (Q36128435)

12 August 2017

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer (English)

1 reference

12 August 2017

0 references

1 reference

21

Marc Ladanyi

1 reference

12 August 2017

28

Rafael Rosell

1 reference

12 August 2017

30

Trever G Bivona

1 reference

12 August 2017

24

Titus J Boggon

1 reference

12 August 2017

Zhenfeng Zhang

1

1 reference

12 August 2017

Jae Cheol Lee

2

1 reference

12 August 2017

Luping Lin

3

1 reference

12 August 2017

Victor Olivas

4

1 reference

12 August 2017

Valerie Au

5

1 reference

12 August 2017

Thomas LaFramboise

6

1 reference

12 August 2017

Mohamed Abdel-Rahman

7

1 reference

12 August 2017

Xiaoqi Wang

8

1 reference

12 August 2017

Alan D Levine

9

1 reference

12 August 2017

Jin Kyung Rho

10

1 reference

12 August 2017

Yun Jung Choi

11

1 reference

12 August 2017

Chang-Min Choi

12

1 reference

12 August 2017

Sang-We Kim

13

1 reference

12 August 2017

Se Jin Jang

14

1 reference

12 August 2017

Young Soo Park

15

1 reference

12 August 2017

Woo Sung Kim

16

1 reference

12 August 2017

Dae Ho Lee

17

1 reference

12 August 2017

Jung-Shin Lee

18

1 reference

12 August 2017

Vincent A Miller

19

1 reference

12 August 2017

Maria Arcila

20

1 reference

12 August 2017

Philicia Moonsamy

22

1 reference

12 August 2017

Charles Sawyers

23

1 reference

12 August 2017

Patrick C Ma

25

1 reference

12 August 2017

Carlota Costa

26

1 reference

12 August 2017

Miquel Taron

27

1 reference

12 August 2017

Balazs Halmos

29

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

12 August 2017

1 reference

12 August 2017

44

1 reference

12 August 2017

852-860

1 reference

12 August 2017

8

1 reference

describes a project that uses

12 August 2017

0 references

0 references

0 references

0 references

0 references

https://scigraph.springernature.com/pub.10.1038/ng.2330

0 references

cites work

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Personalized medicine and inhibition of EGFR signaling in lung cancer

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Determinants for transformation induced by the Axl receptor tyrosine kinase

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3408577

Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer

2 July 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22751098

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NG.2330

1 reference

12 August 2017

1 reference

12 August 2017

1 reference